Abstract
Systemic sclerosis (scleroderma) is a fibrotic condition characterized by immunologic abnormalities, vascular injury, and increased accumulation of extracellular matrix proteins in the affected organs. Although the etiology of scleroderma has not yet been fully elucidated, a growing body of evidence suggests that extracellular matrix overproduction by activated fibroblasts results from a complex interaction among endothelial cells, immunocytes, and fibroblasts, involving a number of mediators such as cytokines, chemokines, growth factors, and their receptors. For a better understanding of the pathophysiology of scleroderma, animal models are important tools. They reproduce several histological as well as biochemical aspects resembling human scleroderma, and we can learn lots of new findings through animal studies. On the other hand, it must be emphasized that there are no animal models so far exhibiting all the aspects of human scleroderma, and studying animal models cannot answer all the problems of human scleroderma. This paper introduces current concepts of various animal models for scleroderma and discusses their advantages/disadvantages, contribution to our understanding of the pathogenesis, and therapeutic approach for human scleroderma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yamamoto T (2009) Scleroderma–pathophysiology. Eur J Dermatol 19(1):14–24. doi:10.1684/ejd.2008.0570
Yamamoto T (2010) Animal model of systemic sclerosis. J Dermatol 37(1):26–41. doi:10.1111/j.1346-8138.2009.00764.x
Yamamoto T (2006) Bleomycin and the skin. Br J Dermatol 155(5):869–875. doi:10.1111/j.1365-2133.2006.07474.x
Mountz JD, Downs Minor MB, Turner R et al (1983) Bleomycin-induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 108(6):679–686. doi:10.1111/j.1365-2133.1983.tb01080.x
Yamamoto T, Takagawa S, Katayama I et al (1999) Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112(4):456–462. doi:10.1046/j.1523-1747.1999.00528.x
Yamamoto T, Takahashi Y, Takagawa S et al (1999) Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol 26(12):2628–2634
Yamamoto T, Kuroda M, Nishioka K (2000) Animal model of sclerotic skin. III: histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 292(11):535–541. doi:10.1007/s004030000183
Yamamoto T, Nishioka K (2001) Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 117(4):999–1001. doi:10.1046/j.0022-202x.2001.01509.x
Yamamoto T, Nishioka K (2002) Animal model of sclerotic skin. V: increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 102(1):77–83. doi:10.1006/clim.2001.5138
Yamamoto T, Nishioka K (2004) Animal model of sclerotic skin. VI: evaluation of bleomycin-induced skin sclerosis in nude mice. Arch Dermatol Res 295(10):453–456. doi:10.1007/s00403-003-0439-y
Shibusawa Y, Negishi I, Tabata Y et al (2008) Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly(L-lactic acid) microspheres. Rheumatology (Oxford) 47(4):454–457. doi:10.1093/rheumatology/ken058
Ishikawa H, Takeda K, Okamoto A et al (2009) Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J Invest Dermatol 129(7):1688–1695. doi:10.1038/jid.2008.431
Yamamoto T, Katayama I (2011) Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol 2011:270938. doi:10.1155/2011/270938
Oi M, Yamamoto T, Nishioka K (2004) Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-‘susceptible’ mouse strains. J Med Dent Sci 51(1):7–17
Ruzehaji N, Avouac J, Elhai M et al (2015) Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis. Arthritis Res Ther 17:145. doi:10.1186/s13075-015-0659-5
Liang M, Lv J, Zou L et al (2015) A modified murine model of systemic sclerosis: bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis. Lab Invest 95(3):342–350. doi:10.1038/labinvest.2014.145
Acknowledgment
This work was supported in part by a grant from project research on intractable diseases from the Japanese Ministry of Health, Labour and Welfare.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Yamamoto, T. (2017). Intradermal Injections of Bleomycin to Model Skin Fibrosis. In: Rittié, L. (eds) Fibrosis. Methods in Molecular Biology, vol 1627. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7113-8_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7113-8_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7112-1
Online ISBN: 978-1-4939-7113-8
eBook Packages: Springer Protocols